DETERMINANTS OF SERUMS CAPACITY OF ACCEPT CHOLESTEROL

血清接受胆固醇能力的决定因素

• 批准号: 2734961
• 负责人: MARGARITA E DE LA LLERA-MOYA
• 金额: $ 8.97万
• 依托单位: ALLEGHENY UNIVERSITY OF HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-07-01 至 1998-11-10
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2734961
• 关键词: blood chemistry; blood disorder; blood lipoprotein metabolism; blood lipoprotein transport; cholesterol; high density lipoproteins; human subject; human tissue; intermolecular interaction; laboratory mouse; lipid transport; membrane model; phosphatidylcholines; radiotracer; tissue /cell culture

Dr. M. E. De La Llera-Moya was born in Cuba and emigrated to this country in 1960. She is a USA citizen. She is a competent scientist and has receive all her scientific training in the States. Dr. Moya has recently moved into an academic research position in the Biochemistry Department at the Allegheny University of the Health Sciences, MCP Hohneman School of Medicine after spending some time directing a specialized clinical lipid laboratory to support a Lipid Disorders Clinic at the Medical College of Pennsylvania Hospital. Dr. Moya has developed an interesting experimental system to investigate the serum factors that affect cellular cholesterol afflux with specific emphasis on the role HDL has in this process. This application centers on further development of this potentially important methodology. Although it is currently thought that the HDL lipoprotein fraction plays a crucial role in the transport of excess tissue cholesterol to the liver for excretion, HDL are heterogeneous and the specific fraction of HDL involved in this important function has not been identified. In addition it is not clear what serum factors interact with HDL to facilitate its cholesterol-transport function. This incomplete understanding of HDL function has important clinical implications since, although high levels of HDL are linked to decreased risk of CAD, not all individuals with abnormally low HDL are equally threatened. Moreover it is not at all clear what are the appropriate therapeutic interventions to modulate HDL levels and reduce CAD risk. Dr. Moya's present appointment in the Biochemistry Department at MCP HSM gives her the best possible support for her work since her sponsor and the other senior members in the department have an established record of successful research in the area of HDL metabolism. Thus all the pertinent equipment, methodology and the expertise will be easily accessible to insure fruitful completion of the work in this application.

M博士E. De La Llera-Moya出生于古巴并移民到这个国家 1960年 她是美国公民。 她是一位称职的科学家， 在美国接受所有的科学训练 莫亚医生最近 进入生物化学系的学术研究职位， 阿勒格尼健康科学大学MCP Hohneman School of 医学经过一段时间的专门指导临床脂质 实验室，以支持脂质疾病诊所在医学院的 宾夕法尼亚医院 莫亚博士发明了一种有趣的实验方法 研究影响细胞胆固醇的血清因子的系统 特别强调HDL在这一过程中的作用。 这 应用程序集中在进一步发展这一潜在的重要 方法论 尽管目前认为HDL脂蛋白 部分在多余组织的运输中起着关键作用 胆固醇被肝脏排泄，高密度脂蛋白是异质的， 参与这一重要功能的HDL的特定部分尚未被 鉴定 此外，尚不清楚血清因子与什么相互作用。 HDL促进其胆固醇运输功能。 这种不完全 对HDL功能的理解具有重要的临床意义， 虽然高水平的HDL与降低CAD风险有关，但并非所有 具有异常低HDL的个体同样受到威胁。 而且它 目前还不清楚什么是适当的治疗干预， 调节HDL水平，降低CAD风险。 莫亚医生目前的任命 在MCP HSM的生物化学系， 她的工作得到了支持，因为她的赞助人和其他高级成员在 该部门在该领域的研究取得了成功的记录 高密度脂蛋白代谢。 因此，所有相关设备、方法和 专业知识将很容易获得，以确保富有成效地完成 在这个应用程序中工作。